Gilead to Initiate P-II/III Study Evaluating Remdesivir in Pediatric Patients Hospitalized With COVID-19
- Gilead will begin enrollment in P-II/III clinical trial assessing the safety- tolerability- PK and efficacy of remdesivir in ~50 pediatric patients with moderate-to-severe COVID-19- including newborns through adolescents
- The trial will be conducted at 30+ sites in the US and EU. Remdesivir is available to pediatric patients with severe COVID-19 under our compassionate use program since Feb’2020 as well as under the US FDA’s EUA
- Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro / in vivo in animal models against multiple emerging viral pathogens- including Ebola- Marburg- MERS and SARS
Click here to read full press release/ article
Ref: Gilead | Image: Gilead
Related News: EMA to Grant Initial Authorization to Gilead’s Remdesivir for COVID-19 is Imminent
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].